Qurient Co. Ltd. and TB Alliance Announce Exclusive License Agreement for Telacebec (Q203), a New Anti-Tuberculosis Agent ...Middle East

Landmark Agreement for New Tuberculosis Treatment SEONGNAM-SI, South Korea and NEW YORK, Feb. 3, 2023 /PRNewswire/ -- Qurient Co. Ltd. ("Qurient", KRX: 115180), a clinical-stage biotechnology company based in South Korea, and TB Alliance, a not-for-profit organization dedicated to the...

Hence then, the article about qurient co ltd and tb alliance announce exclusive license agreement for telacebec q203 a new anti tuberculosis agent was published today ( Friday 03/02/2023 - 09:45 AM ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.

Read More Details
Finally We wish PressBee provided you with enough information of ( Qurient Co. Ltd. and TB Alliance Announce Exclusive License Agreement for Telacebec (Q203), a New Anti-Tuberculosis Agent )

Also on site :

• Person falls to death on Boylston Street on New Year’s Eve
• Suspected mountain lion attack in Colorado mountains under investigation
• Rose Parade 2026: Float riders briefly hold sign seeking fire probe